English Spanish. Urinary Products vs. Treatment Protocols and Monitoring FSH treatment protocols usually include Lupron, Ganirelix, or Cetrotide to control the length of the follicular phase and time ovulation. Learn More. RCC specialists will help you understand your treatment options. Sign up for news and updates. Our Service Areas. Northern Utah. Salt Lake Valley. Utah Valley. Idaho Falls.
Proud Sponsor Of. Get more clinical research insight with our FREE newsletter sign me up. Sign in or Sign-up. News Feature March 31, Menopur Menopur is a hormone treatment. Bravelle Bravelle is a medicine that contains hormones. About Ferring Ferring Pharmaceuticals is a privately owned pharmaceutical company with international interests. I agree to the Terms. I agree to the Privacy Statement. Newsletter Signup. This website uses cookies to ensure you get the best experience on our website.
Learn more. Subject comprehension questionnaires were repeated on Day 6 after 5 days of combination therapy by participants assigned to the Menopur and Bravelle treatment arm. Participants assigned to the Menopur and Bravelle treatment arm read the Mixing Instructions Guide on how to mix and administer the medications at home.
A treatment-emergent AE was any AE occurring after start of investigational medicinal product IMP and within the time of residual drug effect, or a pretreatment AE or pre-existing medical condition that worsened in intensity after start of IMP and within the time of residual drug effect.
The time of residual drug effect was the estimated period of time after the last dose of the IMP, where the effect of the product was still considered to be present based on pharmacokinetic, pharmacodynamic, or other IMP characteristics. Eligibility Criteria. Main Inclusion Criteria: Infertile pre-menopausal female subjects Documented history of infertility eg. Subject's male partner with semen analysis that was at least adequate for intracytoplasmic sperm injection ICSI within 6 months prior to the subjects beginning down-regulation with gonadotropin-releasing hormone GnRH -agonist.
Partners with severe male factor requiring invasive or surgical sperm retrieval or donor sperm could have been used. Main Exclusion Criteria: Oocyte donor or embryo recipient; gestational or surrogate carrier Previous IVF or assisted reproductive technology ART failure due to a poor response to gonadotropins. Inadequate number of oocytes, defined as fewer than 5 oocytes retrieved in previous ART attempts. If either of these conditions existed, the male was to be treated with antibiotics and retested prior to subject's pituitary down-regulation.
Undergoing blastomere biopsy and other experimental ART procedures. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials. More Information. Assisted Reproductive Technology. National Library of Medicine U.
National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Drug: Bravelle Drug: Menopur.
0コメント